Abstract:Backgound: The introduction of the pneumococcal conjugate and polysaccharide vaccines have been valuable tools for combating invasive pneumococcal infection in children and healthy adults. Despite the available vaccination strategies, pneumococcal pneumonia and associated diseases continue to cause substantial morbidity and mortality, particularly in individuals with chronic disease and ageing populations. Next-generation pneumococcal vaccines will need to be highly immunogenic across patient populations providing both mucosal and systemic protective immunity. Mucosal immunization is an effective strategy for stimulating the immune response at the site of pathogen entry while increasing systemic immunity. In this study we utilized intranasal immunization with pneumococcal surface protein A (PspA), in combination with the mucosal adjuvant cholera toxin B (CTB), to characterize the immune components providing protection against S. pneumoniae challenge. Methods: Mice were immunized intranasally with CTB and PspA individually, and in combination, followed by lethal bacterial challenge with S. pneumoniae, strain A66.1. Animals were monitored for survival and tested for lung bacterial burden, cytokine production as well as S. pneumoniae-specific antibody titer in mouse sera. The primary immunological contributor to the observed protection was confirmed by cytokine neutralization and serum passive transfer. Results: The combination of CTB and PspA provided complete protection against bacterial challenge, which coincided with a significant decrease in lung bacterial burden. Increases in the T-helper (Th) 1 cytokines, interferon (IFN)-γ and interleukin (IL)-2 were observed in the lung 24 h post-challenge while decreases in proinflammatory mediators IL-6 and tumor necrosis factor (TNF)-α were also recorded at the same time point. The adjuvanted PspA immunization induced significant titers of S. pneumoniae-specific antibody in the serum of mice prior to infection. Serum adoptive transfer passively protected animals against subsequent challenge while IFN-γ neutralization had no impact on the outcome of immunization, suggesting a primary role for antibody-mediated protection in the context of this immunization strategy. Conclusion: Mucosal immunization with CTB and PspA induced a local cellular immune response and systemic humoral immunity which resulted in effective reduction of pulmonary bacterial burden and complete protection against S. pneumoniae challenge. While induction of the pleiotropic cytokine IFN-γ likely contributes to control of infection through activation of effector pathways, it was not required for protection. Instead, immunization with PspA and CTB-induced S. pneumoniae-specific antibodies in the serum prior to infection that were sufficient to protect against mucosal challenge.

A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice

Protection Elicited by Nasal Immunization with Pneumococcal Surface Protein A (pspa) Adjuvanted with Bacterium-Like Particles Against Streptococcus Pneumoniae Infection in Mice

Broad Protective Immune Responses Elicited by Bacterium-Like Particle-Based Intranasal Pneumococcal Particle Vaccine Displaying PspA2 and PspA4 Fragments.

Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae.

Liposome-based dry powder vaccine immunization targeting the lungs induces broad protection against pneumococcus

Comparison Of Immunogenicity And Protection Of Two Pneumococcal Protein Vaccines Based On Psaa And Pspa

An intranasal cationic liposomal polysaccharide vaccine elicits humoral immune responses against Streptococcus pneumoniae

Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments

A Pneumococcal Vaccine Combination with Two Proteins Containing PspA Families 1 and 2 Can Potentially Protect Against a Wide Range of Streptococcus Pneumoniae Strains

Systemic and Mucosal Immune Responses Elicited by Intranasal Immunization with a Pneumococcal Bacterium-Like Particle-Based Vaccine Displaying Pneumolysin Mutant Plym2.

Immunization With A Zmpb-Based Protein Vaccine Could Protect Against Pneumococcal Diseases In Mice

Immunization with recombinant Streptococcus pneumoniae PgdA protects mice against lung invasion

Mucosal Immunization with Caseinolytic Protease X Elicited Cross-Protective Immunity Against Pneumococcal Infection in Mice.

Utilization of cholera toxin B as a mucosal adjuvant elicits antibody-mediated protection against S. pneumoniae infection in mice

Intranasal Immunization with Autolysin (lyta) in Mice Model Induced Protection Against Five Prevalent Streptococcus Pneumoniae Serotypes in China

Protection Against Pneumococcal Infection Elicited By Immunization With Glutamyl Trna Synthetase, Polyamine Transport Protein D And Sortase A

Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A

Bacterium-like Particles from Corynebacterium pseudodiphtheriticum as Mucosal Adjuvant for the Development of Pneumococcal Vaccines

A protein subunit vaccine elicits a balanced immune response that protects against Pseudomonas pulmonary infection

Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa

Intranasal Immunization with Chitosan-Dna Nanoparticles Expressing Pneumococcal Polyamine Transport Protein D(PotD) Protects Mice Against Streptococcus Pneumoniae Nasopharyngeal Colonization